https://www.pharmatlas.org/ 2026-04-16T17:08:36+00:00 https://www.pharmatlas.org/ https://www.pharmatlas.org/lib/exe/fetch.php?media=logo.png text/html 2026-02-13T00:07:40+00:00 Anonymous (anonymous@undisclosed.example.com) https://www.pharmatlas.org/doku.php?id=endocrine:sglt2:dapagliflozin&rev=1770941260&do=diff Dapagliflozin Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used for diabetes, heart failure, and chronic kidney disease. It provides cardiovascular and renal benefit independent of glucose lowering. → SGLT2 Inhibitors Overview ---------- Mechanism of Action text/html 2026-02-13T00:08:32+00:00 Anonymous (anonymous@undisclosed.example.com) https://www.pharmatlas.org/doku.php?id=endocrine:sglt2:empagliflozin&rev=1770941312&do=diff Empagliflozin Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used for diabetes, heart failure, and chronic kidney disease. It was the first SGLT2 inhibitor to demonstrate cardiovascular mortality reduction. → SGLT2 Inhibitors Overview ---------- Mechanism of Action text/html 2026-02-13T00:09:28+00:00 Anonymous (anonymous@undisclosed.example.com) https://www.pharmatlas.org/doku.php?id=endocrine:sglt2:sotagliflozin&rev=1770941368&do=diff Sotagliflozin Sotagliflozin is a dual SGLT2 and SGLT1 inhibitor used for heart failure and diabetes. Unlike other SGLT2 inhibitors, sotagliflozin also inhibits SGLT1 in the intestine. → SGLT2 Inhibitors Overview ---------- Mechanism of Action SGLT2 inhibition (kidney): text/html 2026-02-13T00:07:01+00:00 Anonymous (anonymous@undisclosed.example.com) https://www.pharmatlas.org/doku.php?id=endocrine:sglt2:start&rev=1770941221&do=diff SGLT2 Inhibitors (Gliflozins) SGLT2 inhibitors are sodium-glucose cotransporter-2 inhibitors that act in the proximal tubule of the kidney. Originally developed for Type 2 Diabetes, they are now foundational therapies in: • Heart Failure • Chronic Kidney Disease • Type 2 Diabetes Mellitus